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Background: Metastatic prostate cancer is a leading cause of cancer-related death in men. Cancer stem cells (CSCs)
are involved in tumor progression and metastasis, including in prostate cancer. There is an obvious and urgent
need for effective cancer stem cells specific therapies in metastatic prostate cancer. MicroRNAs (miRNAs) are an
important class of pervasive genes that are involved in a variety of biological functions, especially in cancer. The
goal of this study was to identify miRNAs involved in prostate cancer metastasis and cancer stem cells.
Methods: A microarray and qRT-PCR were performed to investigate the miRNA expression profiles in PC-3 sphere
cells and adherent cells. A transwell assay was used to evaluate the migration of PC-3 sphere cells and adherent
cells. MiR-143 was silenced with antisense oligonucleotides in PC-3, PC-3-M and LNCaP cells. The role of miR-143 in
prostate cancer metastasis was measured by wound-healing and transwell assays in vitro and bioluminescence
imaging in vivo. Bioinformatics and luciferase report assays were used to identify the target of miR-143.
Results: The expression of miR-143 and the migration capability were reduced in PC-3 sphere cells and
progressively increased during sphere re-adherent culture. Moreover, the down-regulation of miR-143 suppressed
prostate cancer cells migration and invasion in vitro and systemically inhibited metastasis in vivo. Fibronectin type
III domain containing 3B (FNDC3B), which regulates cell motility, was identified as a target of miR-143. The
inhibition of miR-143 increased the expression of FNDC3B protein but not FNDC3B mRNA in vitro and vivo.
Conclusions: These data demonstrate for the first time that miR-143 was up-regulated during the differentiation of
prostate cancer stem cells and promoted prostate cancer metastasis by repressing FNDC3B expression. This sheds a
new insight into the post-transcriptional regulation of cancer stem cells differentiation by miRNAs, a potential
approach for the treatment of prostate cancer.
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Prostate cancer is the most frequently diagnosed malig-
nant disease in men and the second leading cause of
cancer deaths in US [1]. The treatment of prostate cancer
with surgical resection, which may be combined with
chemotherapy, hormone therapy or radiation therapy, is
curative in many patients. However, most patients even-
tually relapse with castration-resistant prostate cancer and
develop metastatic disease, which has a poor prognosis* Correspondence: caiqingqing199@hotmail.com; tianxinl@sina.com
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reproduction in any medium, provided the orbecause no effective treatments are currently available [2].
Although basic knowledge related to metastasis has
increased recently, many of the key elements remain
largely unknown.
Cancer stem cells (CSCs), a small subpopulation of cells
in a tumor, can self-renew and differentiate into multiple
lineages, and they possess strong tumor-initiating capacity.
Therefore, CSCs are thought to be responsible for tumor
initiation, progression, therapy resistance, relapse and me-
tastasis [3]. Accumulating evidence has demonstrated the
existence of prostate cancer stem cells, which can be been
enriched by sorting for CD44+/CD133+ expression [4,5]
or by selecting cells that have the capacity to exclude. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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culture [7,8]. However, the role of prostate cancer stem
cells in tumor development and metastasis is still poorly
understood.
MicroRNAs (miRNAs) are small, noncoding RNAs of
approximately 19 to 25 nucleotides in length that usu-
ally bind to the 30-untranslated region (UTR) of their
mRNA targets, resulting in degradation or translation
repression [9]. Emerging evidence shows that the dysre-
gulation of miRNAs is involved in cancer proliferation,
differentiation, apoptosis and metastasis, and miRNAs
function as oncogenes or tumor suppressors [10]. In
addition, miRNAs have emerged as important regula-
tors of CSCs. Yu and colleagues discovered that let-7
regulates breast tumor-initiating cells properties by
silencing genes involved in self-renewal and differenti-
ation [11]. A recent study has revealed that miR-34a
inhibits prostate cancer stem cells and metastasis by
directly repressing CD44 [12]. It was demonstrated that
miR-320 suppresses the stem cell-like characteristics of
prostate cancer cells by down-regulating the Wnt/beta-
catenin signaling pathway [13].
A series of miRNAs has been identified to be up-
regulated in prostate cancer, including miR-21, miR-24,
miR-32, miR-125b, and miR-221/222. Conversely, miR-
7, miR-34a, miR-101, miR-143/145, and let-7a have
been identified to be down-regulated in prostate cancer
[14]. Furthermore, several miRNAs have been identified
as mediators of metastasis in prostate cancer. It was
demonstrated that miR-221 was progressively reduced
in aggressive and metastasis prostate cancer and
predicted clinical recurrence [15]. A previous study
revealed that miR-21 was overexpressed in prostate can-
cer and promoted apoptotic resistance, invasion and
metastasis by targeting MARCKS [16]. A recent study
has shown that miR-143 plays an important role in
prostate cancer proliferation, migration and chemosen-
sitivity by suppressing KRAS [17]. More recently, miR-
29b was identified as an anti-metastatic miRNA for
prostate cancer cells by regulating epithelial–mesenchy-
mal transition (EMT) signaling [18]. However, the role
of miRNAs in prostate cancer stem cells and metastasis
remains to be elucidated.
In our previous study, we enriched and characterized
prostate cancer stem cells from PC-3 sphere cells in a
defined serum-free medium [7]. In this paper, we use
spheres as a prostate cancer stem cells model to eluci-
date the role of miRNAs in prostate cancer metastasis.
In this study, we compared the miRNA expression pro-
files of PC-3 spheres and adherent cells of prostate
cancer and identified that miR-143 was related to CSCs
and metastasis. Moreover, we demonstrated that the
down-regulation of miR-143 suppressed migration and
invasion in vitro and tumor metastasis in vivo.Methods
Cell culture
The cell lines used in this study included the human pros-
tate cancer cells PC-3, PC-3-M and LNCaP and SV40-
transformed kidney cell line 293 T (ATCC, Manassas,
VA). The prostate cancer cells were cultured in RPMI-
1640 medium and 293 T were cultured in DMEM (Gibco,
Invitrogen) supplemented with 10% FBS (Hyclone). Cells
were grown to 90% confluence, trypsinized, and plated at
a density of 1,000 cells/ml in serum-free DMEM/F12
medium (Gibco, Invitrogen) containing 20 ng/ml epider-
mal growth factor (EGF, R and D Systems, MN), 5 μg/ml
insulin, 0.4% bovine serum albumin (Sigma, St. Louis,
MO), and 2% B27 (Invitrogen, CA) in 10 cm2 culture
dishes. To propagate spheres in vitro, spheres were col-
lected by gentle centrifugation, dissociated to single cells,
and cultured to generate the next generation of spheres
[7]. Cells were grown in a humidified atmosphere of 5%
CO2 at 37°C.
miRNA microarray
Total RNA samples were analyzed by Chipscreen
(Chipscreen Biosciences, Ltd., Shenzhen, China) for
miRNA microarray experiments. Procedures were per-
formed as described in detail (http://www.chipscreen.
com). Each miRNA microarray chip contained 1,199
probes, including 703 identified human miRNAs and
393 predicted miRNAs. The arrays were scanned with a
GenePix Pro 6.0 (Axon, Ltd), and images were analyzed
using DMVS (Chipscreen Biosciences, Ltd.). Microarray
data for each sample were normalized to the median.
All data is MIAME compliant and that the raw data has
been deposited in a MIAME compliant database (GEO,
accession ID: GSE44069).
Quantitative RT-PCR
Total RNA was extracted from cells or tumor tissue of
nude mice using Trizol reagent (Invitrogen) according to
the manufacturer’s protocol. Total RNA was used for re-
verse transcription with the PrimerScript RT-PCR kit
(TaKaRa Biotechnology, Dalian, China). MiRNAs were
reverse transcribed using sequence-specific stem-loop
primers (Invitrogen). Quantitative RT-PCR was con-
ducted using a standard SYBR Green PCR kit (Roche)
protocol with a LightCycler 480 real-time instrument
(Roche). The relative expression was calculated using
the 2-dCt method. The transcription levels of GAPDH or
U6 were used as an internal control. All specific Primers
are listed in Table 1.
Transient transfection
The transfection of PC-3, PC-3-M, and LNCaP cells
with 50 nM miR-143 inhibitor or negative control (NC)
(GenePharma, Shanghai, China) was performed with
Table 1 Oligonucleotide Sequences for (q)RT-PCR and miR-143
Name Sequence
Oct4 Sense primer 50-TCCCATGCATTCAAACTGAGGTGC-30
Antisense primer 50-AACTTCACCTTCCCTCCAACCAGT-30
Sox2 Sense primer 50-TGGACAGTTACGCGCACAT-30
Antisense primer 50-CGAGTAGGACATGCTGTAGGT-30
Nanog Sense primer 50-AAGGTCCCGGTCAAGAAACAG-30
Antisense primer 50-CTTCTGCGTCACACCATTGC-30
GAPDH Sense primer 50-GCACCGTCAAGGCTGAGAAC-30
Antisense primer 50-TGGTGAAGACGCCAGTGGA-30
miR-143 Stem-loop 50-GTCGTATCCAGTGCGTGTCGTGGAGTCGGCAATTGCACTGGATACGA-Ctgagcta-30
U6 Sense primer 50-ACACTCCAGCTGGGTGAGATGAAGCACTGTAG-30
Antisense primer 50-CTCAACTGGTGTCGTGGA-30
FNDC3B Sense primer 50-GCTTCGGCAGCACATATACTAAAAT-30
Antisense primer 50-CGCTTCACGAATTTGCGTGTCAT-30
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turer’s protocol for 48 hours. The sequence of the miR-
143 inhibitor and NC are listed in Table 1Stable miRNA expression cell lines
Lentiviruses containing GFP-miR-143 inhibitor or GFP-
negative control miRNA vector were purchased from
Genepharma. PC-3-M cells were pre-seeded in a 6-well
plate overnight and infected with 200 μl of virus.
24 hours after addition of viruses, infected cells were
selected by adding 20 ng/ml puromycin to growth
medium for 4–5 passages. Stable cell lines were verified
by qRT-PCR and fluorescence microscope.Transwell assay
The transwell assay was done by using transwell chamber
consisting of 8 mm membrane filter inserts (Corning).
The spheres were collected by gentle centrifugation and
trypsinized to single cells in Trypsin-EDTA solution as
well as the adherent cells. The cells were suspended in
serum-free RPMI-1640 medium and counted by auto-
mated cell counter (Countstar). Then 5 × 104 cells were
added to the upper chamber, whereas lower chamber were
filled with complete medium. After 12 hours of incuba-
tion, the cells in the upper chamber were carefully
removed with a cotton swab, and the cells that had
migrated through the membrane to the lower surface were
fixed with 90% methanol and stained with 0.1% crystal vio-
let. The invasion assay was performed according to a simi-
lar method, except that Matrigel (BD Biosciences) waspre-coated on the membrane of the upper chamber. The
cell count was done under the microscope (200×).Wound-healing assay
One day before scratching, the cells transfected with
miR-143 inhibitor or NC were seeded into 6-well plates
to almost total confluence in 24 hours. An artificial
homogenous wound was created onto the monolayer
with a sterile 10 μl tip. After scratching, the cells were
washed with serum-free medium. Images of cells migrat-
ing into the wound were captured at 0 and 24 hours by
inverted microscope (100×).In vivo models of prostate cancer metastasis
All of the animal care and experimental procedures were
approved by the Institutional Animal Care and Use
Committee of Sun Yat-sen University. Male BALB/c
athymic nude mice (4–6 weeks old) were purchased
from the Experimental Animal Center of Guangdong
province and housed in SPF barrier facilities under a
12 h light/dark cycle. PC-3-M cells that stably expressed
miR-143 inhibitor (5 × 106) or NC (5 × 106) were sus-
pended in 100 μl PBS and subcutaneously injected into
the right side of the posterior flank of the mice. Ten
mice were used in each group. Tumor development and
metastases were monitored with a bioluminescence im-
aging system (ZKKS-MulAurora PI1024) on day 30
post-injection. Mice were photographed under 470/
30 nm illumination, and images of the emitted fluores-
cence were acquired at 545/60 nm. Luminescence data
Figure 1 MiR-143 expression was progressively increased during PC-3 spheres differentiation. A, The relative expression of Oct4, Sox2 and
Nanog were analyzed in PC-3 spheres, adherent cells, and re-adherent cells on days 2, and 4 by qRT-PCR (ANOVA). B, The relative expression of
miR-143 in PC-3 spheres and adherent cells was determined by qRT-PCR (Student’s t test). C, The relative expression of miRNAs were analyzed on
days 0, 2, and 4 after PC-3 sphere cells were digested into single cells for re-adherent culture by qRT-PCR (ANOVA) **p < 0.01.
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out pixel saturation (0.5–12 seconds).Bioinformatics
Potential miRNA targets were predicted and analyzed
using two publicly available algorithms, including PicTar
(http://pictar.mdc-berlin.de) and TargetScan (http://www.
targetscan.org/). These searchable websites predict bio-
logical targets of miRNAs by searching for the presence of
conserved 8mer and 7mer sites that match the seed region
of miRNA and provide details 30 UTR alignments with
predicted sites. To decrease the number of false-positive
results only putative target genes predicted by at these two
programs was accepted.Luciferase reporter assays
The 30-UTR luci vector was constructed using the psi-
CHECK2 luciferase reporter vector containing a fragment
of the FNDC3B mRNA 30UTR, which carries a putative
miR-143 complementary site. 293 T cells (5 × 104 per well)
were pre-seeded in a 24-well plate the day before transfec-
tion and transfected with 0.5 μg of the 30 UTR luci vector
and 50 nM miR-143 mimics or negative control using
Lipofectamine 2000 (Invitrogen). Assays were performed
using the Dual-Luciferase Reporter Assay System (Pro-
mega) after 48 hours of transfection.Western blotting
The total protein extracted from the samples was resolved
on 10% sodium dodecyl sulfate–polyacrylamide gels and
electrophoretically transferred to a polyvinylidene fluoride
membrane. Blots were blocked with 5% skim milk fol-
lowed by incubation with antibodies specific for either
FNDC3B (Sigma) or GAPDH (Cell Signaling). The blots
were then incubated with goat anti-rabbit or anti-mouse
secondary antibody (Cell Signaling) and visualized using
enhanced chemiluminescence.
Statistical analyses
Data were presented as the means ± SD from three separ-
ate experiments. The differences between groups were
analyzed using Student’s t test when only two groups were
compared or a one-way analysis of variance (ANOVA)
when more than two groups were compared. The differ-
ences between groups of metastasis in vivo were analyzed
using Chi-squared test (χ2 test). All of the statistical ana-
lyses were performed with SPSS 16.0. The difference was
considered to be statistically significant at P <0.05.
Results
MiR-143 expression was progressively increased during
PC-3 sphere cells differentiation
First, to elucidate whether the PC-3 sphere cells turned
into differentiated cells when sphere cells were digested
Table 2 Differentially expressed miRNAs in PC-3 sphere cells of prostate cancer compared with PC-3 adherent cells by
miRNA microarray and qRT-PCR
Down-regulation Fold change Up-regulation Fold change
Genes Microarray qRT-PCR Genes Microarray qRT-PCR
hsa-miR-143 10.3 8.4 ± 0.57 hsa -miR-202 11.8 7.9 ± 1.84
hsa -miR-19a* 6.8 7.1 ± 1.13 hsa -miR-96* 8.7 5.2 ± 2.37
hsa -miR-125b 6.4 5.8 ± 0.79 hsa -miR-377 3.9 4.0 ± 0.39
hsa -miR-16 3.2 3.8 ± 1.61 hsa -miR-802 4.7 3.7 ± 0.84
hsa -miR-675 2.2 3.1 ± 0.42 hsa -miR-606 4.4 3.2 ± 0.68
hsa -miR-92a 4.3 2.9 ± 0.73 hsa-miR-142 3.1 3.1 ± 0.32
hsa -miR- let-7i 5.1 2.8 ± 0.32 hsa-miR-590 4.1 3.0 ± 0.53
hsa -miR-34a 3.0 2.7 ± 0.29 hsa-miR-376c 3.4 2.8 ± 0.32
hsa -miR-616 2.9 2.7 ± 0.65 hsa-miR-19a 3.0 2.7 ± 0.34
hsa -miR-933 2.9 2.5 ± 0.51 hsa-miR-381 2.4 2.7 ± 0.54
hsa -miR-17 3.7 2.4 ± 0.27 hsa-miR-19b 2.8 2.5 ± 0.42
hsa -miR-365 2.6 2.4 ± 0.39 hsa-miR-28 3.2 2.4 ± 0.57
hsa -miR-135b* 2.6 2.3 ± 0.41 hsa-miR-488* 3.0 2.4 ± 0.38
hsa -miR-939 3.4 2.3 ± 0.69 hsa-miR-18b 2.1 2.3 ± 0.42
hsa-miR- let-7c* 2.4 2.2 ± 0.28 hsa-miR-137 2.7 2.3 ± 0.63
hsa -miR-24 2.3 2.1 ± 0.33 hsa-miR-216b 2.6 2.2 ± 0.28
hsa -miR-10a 2.3 2.1 ± 0.45 hsa-miR-337 2.0 2.1 ± 0.23
hsa -miR-205 4.2 2.0 ± 0.25 hsa-miR-30a 2.3 2.0 ± 0.45
hsa -miR-584 2.8 2.0 ± 0.49 hsa-miR-452* 2.3 1.8 ± 0.25
hsa -miR-125a 2.5 1.9 ± 0.39 hsa-miR-570 2.2 1.4 ± 0.39
hsa -miR-574 2.3 1.8 ± 0.64 hsa-miR-301b 2.1 1.3 ± 0.52
hsa -miR-361 2.2 1.7 ± 0.44 hsa-miR-379 2.1 1.0 ± 0.35
hsa -miR- let-7 g 2.2 1.7 ± 0.65 hsa-miR-22 2.0 0.9 ± 0.56
hsa -miR-885 2.2 1.5 ± 0.34 hsa-miR-545* 2.0 0.7 ± 0.44
hsa -miR-325 2.1 1.4 ± 0.39 hsa-miR-922 2.0 0.5 ± 0.29
hsa -miR-9* 2.1 1.3 ± 0.52
hsa -let-7c* 2.1 1.3 ± 0.26
hsa -miR-27b 2.0 1.2 ± 0.44
hsa -miR-296 2.3 1.1 ± 0.35
hsa -miR-630 2.0 1.1 ± 0.22
hsa-miR-138 2.0 1.0 ± 0.39
hsa-miR-936 2.0 1.0 ± 0.35
hsa-let-7e 2.0 1.0 ± 0.55
hsa-miR-513 2.0 0.9 ± 0.51
hsa-miR-135b* 2.1 0.9 ± 0.24
has-miR-845 2.0 0.8 ± 0.19
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1640 medium), we compared the expression levels of can-
cer stem cells markers, such as Oct4, Sox2 and Nanog by
qRT-PCR. The expression of Oct4, Sox2 and Nanog were
gradually decreased in re-adherent culture (Figure 1A).
This suggested that PC-3 sphere cells had the cancer stemcells phenotype and differentiated in re-adherent culture.
Second, to investigate whether miRNAs were differentially
expressed in PC-3 spheres and adherent cells, we com-
pared miRNA expression profiles using a miRNA micro-
array. We observed the increased expression of 25
miRNAs and decreased expression of 36 miRNAs in PC-3
Figure 2 The migration of PC-3 sphere cells was gradually enhanced in differentiation. A, The migration capacity of PC-3 sphere cells and
adherent cells was analyzed by transwell assays. Five predetermined fields were photographed at 200x magnification, and cells were counted and
analyzed with a histogram (31.5 ± 3.5 versus 122.0 ± 12.5, Student’s t test). B, The migration capacity of re-cultured sphere cells on days 1, 2, 3,
and 4 was tested by transwell assays. (ANOVA) **p < 0.01.
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to confirm our microarray data, qRT-PCR was performed
to analyze the expression of the most significantly differ-
entially expressed miRNAs (Table 2). The expression of
miR-143 was down-regulated 8.4-fold in PC-3 sphere cells
compared with adherent cells (Figure 1B). Next, we tested
10 miRNAs for which the expression levels were most
changed during PC-3 sphere cells re-adherent culture on
days 0, 2, and 4 by qRT-PCR. The expression of miR-143
was progressively increased during re-adherent culture,
but no significant change was observed for the other 9
miRNAs (Figure 1C). Therefore, we selected miR-143 to
further investigate its role in prostate cancer. These results
suggested that miR-143 might play a regulatory role in
prostate cancer stem cells differentiation in vitro.
PC-3 sphere cells migration was gradually enhanced in
differentiation
To evaluate the metastatic mechanism of prostate cancer
stem cells, we compared the migration capacity of PC-3
spheres and adherent cells with a transwell assay. Interest-
ingly, less PC-3 sphere cells penetrated through the gel-
membrane compared with adherent cells (Figure 2A).
However, when we digested the sphere cells into single
cells for re-adherent culture, the cells gradually showed
increased migration capability and reached the level of ad-
herent cells on the fourth day (Figure 2B). These data
suggested that prostate cancer stem cells might exhibit
lower metastatic ability but generate differentiated cells
expressing a highly aggressive phenotype.
Down-regulation of miR-143 inhibited prostate cancer
cells migration and invasion in vitro
MiR-143 expression and cells migration were increased
during sphere cells differentiation. To evaluate whethermiR-143 played an important role in the metastasis of
prostate cancer cells, we decreased the expression of miR-
143 in PC-3, PC-3-M and LNCaP cells by transient trans-
fection with siRNA. MiRNA negative control-transfected
cells, PC-3/NC, PC-3-M/NC and LNCaP/NC, were used
as control groups. As shown in Figure 3A, the relative ex-
pression of miR-143 in PC-3, PC-3-M and LNCaP cells
transfected with the miR-143 inhibitor was approximately
10-fold lower compared with cells transfected with NC.
Migration and invasion assays were performed in vitro. In-
triguingly, in wound-healing and transwell assays, cells mi-
gration was much slower and fewer cells penetrated
through the gel-membrane when cells transfected with the
miR-143-inhibitor compared with NC (Figure 3B,C).
Moreover, cells invasion was markedly inhibited by the
transfection with the miR-143 inhibitor (Figure 3D). These
data strongly suggest that inhibition of miR-143 repressed
the migration and invasion of prostate cancer cells
in vitro.
Down-regulation of miR-143 repressed PC-3-M metastasis
in vivo
To further explore the effect of miR-143 on prostate
cancer metastasis in vivo, PC-3-M cells were stably trans-
fected with NC or miR-143 inhibitor and subcutaneously
injected into nude mice. As shown in Figure 4A, the
relative expression of miR-143 in PC-3-M cells transfected
with the miR-143 inhibitor was stably about 10-fold lower
compared with cells transfected with NC at least 60 days.
The development and metastasis of tumors in vivo were
monitored by visualizing the bioluminescence emitted
from the luciferase-tagged tumors on day 30. Mice injected
with the miR-143 inhibitor PC-3-M cells developed fewer
systemic metastasis (2/10 versus 8/10), especially fewer
macroscopic and bioluminescent nodes in the liver (3/10
Figure 3 The down-regulation of miR-143 inhibited prostate cancer cells migration and invasion in vitro. A, The down-regulation of miR-
143 in PC-3, PC-3-M and LNCaP cells by siRNA was verified by qRT-PCR. B-C, The migration of cells in which miR-143 was down-regulated was
analyzed by a wound-healing assay and transwell assays. D, The invasive properties of the indicated cells were evaluated in an invasion assay
using a transwell insert coated with Matrigel. Penetrated cells were counted and analyzed with a histogram (* P < 0.05, ** P < 0.01, Student’s
t test).
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Figure 4 The down-regulation of miR-143 repressed PC-3-M metastasis in vivo. A, The down-regulation of miR-143 in PC-3-M stable cell
lines on days 0 and 60 by shRNA was verified by qRT-PCR. B, Systemic metastases of PC-3-M cells was measured in mice by bioluminescence
imaging 30 days post-implant. C, The liver metastasis of PC-3-M cells was measured by macroscopic and bioluminescent methods after autopsy.
D, Histologic analysis of metastatic lesions in the ribs of nude mice was carried by H&E-staining in which tumors were marked as “T”, bone was
“B” and muscle was “M”.
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(Figure 4B,C, Table 3). Histological confirmations were
made by H&E-stainning (Figure 4D). Mice injected with
the miR-143 NC PC-3-M cells developed severe metastatic
lesions in the ribs of nude mice, and only a litter bone and
muscle were residual. However, no bone metastasis was
seen in the mice implanted with miR-143 inhibitor cells.
These findings suggested that the down-regulation of miR-
143 inhibited prostate cancer cells metastasis in vivo.
MiR-143 targeted oncogene FNDC3B
To elucidate the mechanisms through which miR-143
induced prostate cancer cells metastasis, two publicly avail-
able algorithms were used to help predict miR-143 targets.
Among the approximately 200 candidate genes, fibronectin
type III domain containing 3B (FNDC3B) was a high-
scoring candidate. FNDC3B is a member of the fibronectinTable 3 Incidence of systemic and liver metastasis in
transplanted nude mice treated with miR-143 inhibitor or
NC
Systemic metastasis Liver metastasis
NC 8/10 9/10
MiR-143 inhibitor 2/10 3/10
p (χ2 test) 0.023* 0.02*
*, p < 0.05.family, which regulates cell motility, and is down-regulated
in tumor cells with high metastatic potential [19]. Zhang
et al. [20] reported that up-regulated miRNA-143 enhanced
hepatocarcinoma metastasis by repressing FNDC3B ex-
pression. Thus, we focused on the possible regulation of
FNDC3B by miR-143. As shown in Figure 5A, miR-143
was partially complementary to the FNDC3B mRNA 30 un-
translated region (UTR) element. Consequently, a luciferase
reporter assay was performed to verify whether miR-143
could directly target the FNDC3B 30-UTR. The luciferase
activity of psi-CHECK2-FNDC3B was obviously decreased
in the presence of miR-143, whereas no significant reduc-
tion was observed when cells were cotransfected with NC
(Figure 5B). Moreover, we evaluated the effects of miR-143
on FNDC3B mRNA and protein levels in PC-3-M cells by
RT-PCR and western blotting. FNDC3B mRNA levels
showed no significant change whereas protein levels were
increased in PC-3-M cells transfected with miR-143-
inhibitor (Figure 5C). We also investigate the expression of
miR-143 and FNDC3B in the tumor tissue of nude mice by
RT-PCR and western blotting. As expected, the expression
of miR-143 was significantly decreased whereas FNDC3B
protein levels were enhanced in the tumor tissue of the
group of miR-143-inhibitor (Figure 5D). Taken together,
these findings suggested that miR-143 might modulate
prostate cancer metastasis by targeting FNDC3B.
Figure 5 MiR-143 targeted oncogene FNDC3B. A, The putative miR-143-binding sequence was in the 30-UTR of FNDC3B mRNA. B, The dual
luciferase report assay of HEK-293 T cells cotransfected with psi-CHECK2-FNDC3B and miRNA (miR-143, NC). The Renilla luciferase signals were
normalized to the internal firefly luciferase transfection control. C, The mRNA and protein expression of FNDC3B in PC-3-M cells transfected with
miR-143 inhibitor or NC was analyzed by RT-PCR (above) and western blotting (below). D, The expression of miR-143 and FNDC3B in the tumor
tissues of nude mice were analyzed by RT-PCR (above) and western blotting (below). U6 and GAPDH were internal control. (* P < 0.05).
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Cancer stem cells (CSCs) are involved in tumor progres-
sion and metastasis and are associated with increased
aggressiveness and metastasis in vivo [5,12]. In our pre-
vious study, we enriched prostate cancer stem cells from
PC-3 sphere cells in serum-free suspension culture and
characterized their CSCs properties [7]. Several
published reports have demonstrated that non-adherent
spheres culture is increasingly used as an effective
method to enrich and identify stem cells or putative
CSCs [8,11,21]. Thus, we used spheres as a prostate can-
cer stem cells model to elucidate its metastatic mechan-
isms. Moreover, the expressions of cancer stem cells
markers, such as Oct4, Sox2 and Nanog were gradually
decreased when the sphere cells were digested into sin-
gle cells for re-adherent culture. Interestingly, our results
showed that sphere cells exhibited lower migration in a
transwell assay, but the migration capability was grad-
ually increased during the sphere cells differentiation. In
fact, when growth factors were removed and the cells
were exposed to 10% FBS-containing medium, sphere
cells gradually became adherent, flat monolayer cells,
which demonstrated the parental cell phenotype [11,22].
A recent study revealed that prostate cancer stem cells
were able to generate differentiated cells expressing ei-
ther a high- or low-level aggressive phenotype in vitro
[22]. Taken together, our findings suggest that prostate
cancer stem cells may exhibit lower metastasis but gen-
erate highly aggressive cells after differentiation in vitro.
In this study, we found that miR-143 was decreased in
prostate cancer stem cells and progressively increased
during the sphere cells differentiation. Furthermore, thedown-regulation of miR-143 inhibited prostate cancer
cells migration and invasion in vitro and metastasis
in vivo. However, our results are inconsistent with some
reports that miR-143 was down-regulated in several can-
cer tissues compared to normal tissue and was identified
as a tumor suppressor [17,23,24]. A recent study showed
that miR-143, miR-16 and miR203 modulated cell prolif-
eration and manifested tumor suppressive effects in ER
positive breast cancer [23]. The overexpression of
miRNA-143 in bladder cancer cells significantly inhib-
ited cell proliferation and RAS protein expression [24].
Bin X et al. [17] showed that miR-143 inhibited prostate
cancer cells proliferation and migration through sup-
pressing KRAS.
Conversely, some reports found that miR-143 was
overexpressed in cancer samples [25,26]. A recent study
revealed that miR-143 and miR-145 were overexpressed in
invasive subpopulations of glioblastoma, and their down-
regulation abrogated invasion [27]. Moreover, it was
demonstrated that the up-regulation of miR-143 expression
in hepatocellular carcinoma (HCC) promoted cancer cells
metastasis by repressing FNDC3B. Overexpression of miR-
143 promoted HCC local liver metastasis and distant lung
metastasis in nude mouse model, but metastasis could be
significantly inhibited by blocking miR-143 [20]. These
results are consistent with our findings that miR-143 pro-
motes prostate cancer cell metastasis by targeting FNDC3B.
Taken together, this discrepancy could be due to the multi-
functional nature of miRNAs. These findings indicate that
miR-143 has the potential to regulate cell biology by modu-
lating the expression of different target genes. Furthermore,
the expression of miR-143 and FNDC3B in human clinical
Fan et al. BMC Cancer 2013, 13:61 Page 10 of 11
http://www.biomedcentral.com/1471-2407/13/61prostate cancer specimens is still unclear. Further investiga-
tion on the relationship between their expression level and
metastasis, and its potential significance in prostate cancer
metastasis, is underway in the laboratory.
Conclusion
It is our novel discovery that miR-143 was up-regulated
during the differentiation of prostate CSCs and promoted
prostate cancer metastasis by repressing FNDC3B expre-
ssion. Our results suggested that miR-143 might play a
critical role in prostate cancer differentiation, which may
generate highly aggressive cells to promote metastasis,
and provide a potential development of a new approach
for the treatment of metastatic prostate cancer.
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